Ohad D. Rotenberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/2e13dc30-c4aa-11eb-925b-439657343c68.jpg

First Name

Ohad

Last Name

Rotenberg

NPI

1770663338

Faculty ID

4113

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3947

Is Open Scheduling

Off

Sara S. Rabin-Havt

https://assets.montefioreeinstein.org/profiles/images/physphoto/Rabin_Havt_Sara_MD_420x504.jpg

First Name

Sara

Last Name

Rabin-Havt

NPI

1194098509

Faculty ID

16281

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Reproductive and medical genetics, specifically prenatal and preconception consultation and testing and consultation and testing for hereditary cancer syndromes.

Research Focus

Principal investigator on a multi-center study investigating the genetic etiologies of non-immune fetal hydrops (NIHF). In addition, I participate in studies examining access to genetic consultation and testing pre- and post-pandemic

Elsevier Profile

EMR ID

55649

Biography

<p>Sara Schonfeld Rabin-Havt, MD, FACOG, FACMG is an attending physician and assistant professor in the division of Reproductive and Medical Genetics at Montefiore Einstein. Her clinical focus lies in prenatal and preconception genetic counseling, screening and testing; prenatal diagnosis; evaluation of recurrent pregnancy loss; genetic counseling and testing for hereditary cancer syndromes.</p><p>After earning her Bachelor of Arts from Cornell University (2005) and her Doctor of Medicine from Mt. Sinai School of Medicine (2009), Dr. Rabin-Havt came to Montefiore Einstein to complete residency in Obstetrics &amp; Gynecology and Women&rsquo;s Health (2013). She worked as a generalist in private practice before returning to Montefiore Einstein to complete a residency in medical genetics and genomics (2019).</p><p>Building on her clinical focus, Dr. Rabin-Havt is a principal investigator on a multi-center study investigating the genetic etiologies of non-immune fetal hydrops (NIHF). In addition, she participates in resident, fellow and medical student education and has been inducted into the Leo M. Davidoff Society for Outstanding Achievement in medical student teaching at Einstein. Her work has been published in numerous peer-reviewed journals.</p><p>Dr. Rabin-Havt is a fellow of the American College of Obstetrics and Gynecology (ACOG) and the American College of Medical Genetics (ACMG). She has served as a board member of the NYS Genetics Task Force and a committee member of the American College of Medical Genetics (ACMG) committee on Social, Ethical, and Legal issues (SELI). She was a member of the curriculum committee of the CREOG Cancer Genetics Curriculum which is available to OB/GYN residents nationwide.</p><p>Dr. Rabin-Havt is board certified by the American Board of Obstetrics and Gynecology (ABOG) and the American Board of Medical Genetics and Genomics (ABMGG).</p>

Is Open Scheduling

Off

Paul A. Levy

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e14d37b0-ab9e-11ed-b3ca-abfc451c1751.jpg

First Name

Paul

Last Name

Levy

NPI

1356429518

Faculty ID

3077

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

3884

Biography

<p>Paul Levy, MD, is Director, Center for Inherited Metabolic Disorders and Director, Inherited Metabolic Disease Specialty Care Referral Center at the Children&rsquo;s Hospital at Montefiore Einstein. He is also Associate Professor, Pediatrics and Pathology at our Albert Einstein College of Medicine. Dr. Levy sees patients with complex medical issues that may have a genetic etiology. He has a special interest in inherited metabolic disorders, including phenylketonuria (PKU), lysosomal storage diseases and urea cycle disorders, and sees newborns referred by the New York State Newborn Screening Program with positive screens.
</p><p>After earning his Doctor of Medicine at Tulane University, Dr. Levy completed his residency in pediatrics at Montefiore Einstein. He then completed a fellowship in ambulatory pediatrics at the same institution. Following this, Dr. Levy completed a fellowship in clinical and biochemical genetics at Tulane University. </p><p>Dr. Levy is involved in a long-term follow-up study for children with disorders diagnosed by newborn screening. He also participates in a study looking into a novel way to look at newborn screening and follow-up testing to determine if some infants with positive newborn screens may have a late-onset disease such as Pompe, Krabbe, and mucopolysaccharidosis (MPS I). Dr. Levy is on an advisory panel for Krabbe disease that helps physicians interpret clinical data to help determine infants&rsquo; status and help with needed follow-up. He has been principal investigator and co-investigator on clinical trials and funded research projects, and his work has been published in numerous peer-reviewed journals, review articles, book chapters and meeting abstracts. Dr. Levy has also given several nationally invited presentations and has been a journal reviewer for <em>Pediatrics Journal of Pediatrics and Genetics in Medicine</em>. </p><p>Dr. Levy is a Diplomat of the National Board of Medical Examiners and is board certified by the American Board of Pediatrics and the American Board of Medical Genetics. He is a member of many professional organizations, including the American Academy of Pediatrics, the American Society of Human Genetics, Society for Inherited Metabolic Disorders and the American College of Medical Genetics and Genomics. In 2023, Dr. Levy received the &ldquo;Clinician Champion Award in Newborn Screening&rdquo; from the Association of Public Health Laboratories.
</p>

Is Open Scheduling

Off

Matthew Levitus

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Matthew

Last Name

Levitus

NPI

1205219425

Faculty ID

16738

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

13410

Is Open Scheduling

Off

Susan D. Klugman

https://assets.montefioreeinstein.org/profiles/images/physphoto/Klugman_Susan_MD_420x504.jpg

First Name

Susan

Last Name

Klugman

NPI

1649350117

Faculty ID

2154

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Klugman is a "medical detective" who works to identify the possible genetic risk factors for many inherited diseases. She encourages couples to consider genetic testing even before they get married so they can be as informed as possible when planning their families. Dr. Klugman’s clinical focus is on the evaluation of patients and families at risk for genetic disorders during pregnancy or preconception, including prenatal diagnosis and consultation for patients undergoing assisted reproductive technologies. She also provides evaluations for patients at risk for hereditary cancer syndromes.

Dr. Klugman has appeared on ABC World News Tonight with Diane Sawyer and WABC-TV Ch. 7. She has also been profiled and quoted in numerous articles in the Westchester Journal News.</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

&nbsp;Dr. Klugman&rsquo;s clinical focus is on the evaluation of patients and families at risk for genetic disorders during pregnancy or preconception, including prenatal diagnosis and consultation for patients undergoing assisted reproductive technologies. She also provides evaluations for patients at risk for hereditary cancer syndromes.

Research Focus

Dr. Klugman&rsquo;s research focuses on novel methods for prenatal screening, testing and diagnosis as well as the assessment of new modalities for diagnoses and treatment of hereditary cancer syndromes.

Elsevier Profile

Selected Publications

<p>Syeda M, Upadhyay K, Loke J, <strong>Klugman S</strong>, Pearlman A, Shao Y, Ostrer H,<em> Prediction of breast&nbsp;<em>cancer risk based on flow variant analysis of circulating peripheral blood B cells,&nbsp;</em>Genetics in Medicine, March 16, 2017</em></p>
<p>Aung C, Greb A, Kalia I, Bajaj K, <strong>Klugman S</strong>, <em>Patient Perspectives on Intimate Partner Violence Discussion during Genetic Counseling Sessions</em>, Journal of Genetic Counseling, December 9, 2016</p>
<p>Wiesman C, Rose E, Grant A, Zimlover A, <strong>Klugman S</strong>, Schreiber-Agus N, <em>Experiences from a pilot program bringing BRCA1/2 genetic screening to the U.S. Ashkenazi Jewish population - The BRCAcommunity Initiative: Results and Reflections from Year 1, </em>Genetics in Medicine, October 2016</p>
<p>Gregg A, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, <strong>Klugman S</strong>, Watson MS, <em>Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics</em>, Genetics in Medicine, October 18 2016</p>
<p>Shani H, Goldwaser T, Keating J, <strong>Klugman S, </strong><em>Chromosomal abnormalities not currently detected by cell-free fetal DNA: a retrospective analysis at a single center,</em> American Journal of Obstetrics and Gynecology, Jun 2016; 214(6):729.e1-729.</p>
<p>Rose E, Schreiber-Agus N, Bajaj K, <strong>Klugman S</strong>, Goldwaser T. <a href="http://www.ncbi.nlm.nih.gov/pubmed/26354339"><em>Challenges of Pre- and Post-Test Counseling for Orthodox Jewish Individuals in the Premarital Phase.</em></a> Journal of Genetic Counseling. 2016 Feb;25(1):18-24.</p>
<p>Wiesman C, Rose E, <strong>Klugman S</strong>, Schreiber-Agus N. <a href="http://www.ncbi.nlm.nih.gov/pubmed/26611540"><em>From Campers to Counselors: a Resource for Prospective Genetic Counseling Students.</em></a>Journal of Genetic Counseling. 2015 Nov 27</p>
<p>Ferraira, JC, Shreiber-Agus N, Carter SM, <strong>Klugman S,</strong> Grieg AR, Gross SJ <em>Carrier&nbsp;<em>testing for Ashkenazi Jewish disorders in the prenatal setting: navigating the genetic maze</em>, American Journal of Obstetrics &amp; Gynecology, 2014 Sept (3) 194-204.</em></p>
<p><strong>Klugman S</strong>, Dolan SM. <em>Expanded genetic testing in assisted reproductive technology: lessons learned from prenatal testing</em>. Virtual Mentor 2014 Jan 1;(16)1: 38-42</p>
<p><strong>Klugman S, </strong>Suskin,B, Spencer B, Dar P, Bajaj K, Powers, J, Reichling J, Wasserman D,&nbsp;Dolan S, Merkatz I.&nbsp;<em>Clinical Utility of Chromosomal Microarray Analysis in Prenatal&nbsp;<em>Diagnosis: Report of First 6 Months in Clinical Practice&nbsp;</em>The Journal of Maternal-Fetal and&nbsp;Neonatal Medicine 2013 Nov 26</em></p>
<p><strong>Klugman S,</strong> Schreiber-Agus N, Nazareth S<strong>, </strong>Evans, E<em>Detection of Carriers in the Ashkenazi Jewish Population: An Objective Comparison of High-Throughput Genotyping vs Gene by Gene </em>Genetic Testing and Molecular Biomarkers 2013 Oct;17(10):763-7</p>
<p>Guti&eacute;rrez JF, Bajaj K,&nbsp;<strong>Klugman</strong><strong>&nbsp;</strong><strong>SD</strong>. <em>Prenatal screening for fragile x: carriers, controversies, and counseling. </em>Reviews in Obstetrics and Gynecology 2013;6(1):e1-7</p>
<p class="desc"><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Rinella%20ES%5BAuthor%5D&amp;ca… ES</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Shao%20Y%5BAuthor%5D&amp;cautho… Y</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Yackowski%20L%5BAuthor%5D&amp;c… L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Pramanik%20S%5BAuthor%5D&amp;ca… S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Oratz%20R%5BAuthor%5D&amp;cauth… R</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Schnabel%20F%5BAuthor%5D&amp;ca… F</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Guha%20S%5BAuthor%5D&amp;cautho… S</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=LeDuc%20C%5BAuthor%5D&amp;cauth… C</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Campbell%20CL%5BAuthor%5D&amp;c… CL</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Klugman%20SD%5BAuthor%5D&amp;ca…; <strong>SD</strong></a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Terry%20MB%5BAuthor%5D&amp;caut… MB</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Senie%20RT%5BAuthor%5D&amp;caut… RT</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Andrulis%20IL%5BAuthor%5D&amp;c… IL</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Daly%20M%5BAuthor%5D&amp;cautho… M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=John%20EM%5BAuthor%5D&amp;cauth… EM</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Roses%20D%5BAuthor%5D&amp;cauth… D</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chung%20WK%5BAuthor%5D&amp;caut… WK</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Ostrer%20H%5BAuthor%5D&amp;caut… H</a>. <em>Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation</em> Hum Genet 2013 May 132(5) 523-26.</p>
<p class="desc">Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, Savage M, Platt LD, Saltzman D, Grobman WA, <strong>Klugman S</strong>, Scholl T, Simpson JL, McCall K, Aggarwal VS, Bunke B, Nahum O, Patel A, Lamb AN, Thom EA, Beaudet AL, Ledbetter DH, Shaffer LG, Jackson L. <em>Chromosomal microarray versus karyotyping for prenatal diagnosis. </em>New England Journal of Medicine 2012 Dec &nbsp;&nbsp;&nbsp;6:367(23) 2175-8</p>
<p>Robin,NH, Reid Sutton V, Caldwell J, Jackson J, Irons M, Demmer L, Byers P, Ellison J,&nbsp;Feldman J, Gross S,&nbsp;<strong>Klugman S</strong>, Adam A, Keppler-Noreuil K, Hopkin R, McCandless S,&nbsp;Sharer D, Wiesner G, Pyeritz R, Westerman J&nbsp;&nbsp;&nbsp;&nbsp;<em>The development and implementation of an&nbsp;<em>In-service exam for medical genetics residency programs.&nbsp;</em>Genetics in Medicine 2012 May 14&nbsp;(5):552-7</em></p>
<p>Yachelevich N, Gittler JK, <strong>Klugman S</strong>, Feldman B, Martin J, Brooks&nbsp; SS, Dobkin C, Nolin SL. <em>Terminal deletions&nbsp; of the long arm of chromosome X that include the FMR1 gene in female patients: A case series.</em> American Journal of Medical Genetics A. 2011 Apr;155(4):870-4.</p>
<p class="desc">Gross, SJ, Bajaj K, Garry D, <strong>Klugman S</strong>, Karpel BM, Roe AM Wagner BJ, Zhan J, Apfelroth SD, Schreiber-Agus N: <em>Rapid and novel prenatal molecular assay for detecting aneuploides and microdeletion syndromes</em>. Prenatal Diagnosis 2011 31(3):259-66</p>
<p class="desc">Ram, KT, <strong>Klugman, SD</strong>: <em>Best practices: antenatal screening for Common genetic conditions other than aneuploidy</em>. Current Opinions in Obstetrics and Gynecology 2010 22(2):139-45&nbsp;</p>
<p class="desc"><strong>Klugman, S,</strong> Gross, SJ: Ashkenazi Jewish screening in the twenty-first century. Obstetric and Gynecologic Clinics of North America 2010 37(1): 37-46&nbsp;&nbsp;</p>
<p class="desc">Rybak, EA, Beviliacqua, K, Veit, CR, <strong>Klugman, SD</strong>, Santoro N: <em>Sibling and self ovum donation for sisters with an intermediate FMR1 mutation: what's a program to do. </em>Fertility and Sterility 2009 92(1): 394</p>
<p class="desc"><strong>Klugman, S</strong>, Gross SJ, Khabele D, Liang, J, Lopez-Jones, M, Gross, B, Cordero, DR, Reznik, S: <em>Expression of Keratin 8 and TNF-Related Apoptosis-I Inducing Ligand (TRAIL) in Down Syndrome Placentas</em>. Placenta 2008 29(4):382-4</p>
<p class="desc">Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, <strong>Klugman S</strong>, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, TrippT, Bianchi DW, D&rsquo;Alton ME; <em>First and second Trimester screening detection of aneuploides other than Down Syndrome.</em>&nbsp; Obstetrics and Gynecology 2007 110(3):651-7</p>
<p class="desc">Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, KharbutliY, Porter TF, Luthy DA, Comstock CH, Saade GR, <strong>Klugman S</strong>, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR Wolfe HM, D&rsquo;Alton ME. <em>Pregnancy loss rates after midtrimester Amniocentesis. </em>Obstetrics and Gynecology. 2006 108:1067-72</p>
<p>Lambert-Messerlian, G., Dugoff, L., Vidaver, J., Canick, J.A., Malone, F.D., Ball, R.H., Comstock, C.H., Nyberg, D.A., Saade, G., Eddleman, K., <strong>Klugman, S</strong>., Craigo, S.D., Timor-Tritsch, I.E., Carr, S.R., Wolfe, H.M. &amp; D&rsquo;Alton, M.E. (2006). <em>First- and second-trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): A FASTER trial study.</em>&nbsp; Prenatal Diagnosis, 26(8):672-8.</p>
<p class="desc"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retriev… DR, Goldberg Y, Basel D, Kilpatrick MW, <strong>Klugman S</strong>, Tsipouras P, Gross S.</a><em>Prenatal sonographic diagnosis of Grebe syndrome.</em> Journal of Ultrasound in Medicine. 2006 (1):115-8</p>
<p>Cleary-Goldman J, Malone FD, Vidaver J, Ball RH, Nyberg DA, Comstock CH, Saade GR, Edelmann KA, <strong>Klugman S</strong>, Timor-Tritsch IE, Craigo SD, Carr SR, Wolfe HM, Bianchi DW, D&rsquo;Alton M<em> Faster Consortium, &ldquo;Impact of maternal age on obstetric outcome.&rdquo; </em>Obstetrics and Gynecology 2005 Vol. 105(5 Pt 1):983-90</p>

EMR ID

3754

Biography

<p>Susan Klugman, MD, FACOG, FACMG, is Director, Reproductive and Medical Genetics, Program Director, Medical Genetics and Genomics Residency and Professor, Obstetrics &amp; Gynecology and Women&rsquo;s Health and Pediatrics at Montefiore Einstein. Her clinical focus is on the evaluation of patients and families at risk for genetic disorders including those patients at risk for hereditary cancer syndromes. She also provides evaluations during pregnancy or preconception, including prenatal diagnosis and consultation for patients undergoing assisted reproductive technologies.</p><p>After completing her Bachelor of Science at Cornell University in 1984, Dr. Klugman attended New York University School of Medicine, earning her Doctor of Medicine in 1988. She pursued her postdoctoral training at Montefiore Einstein and Jacobi Medical Center, completing her obstetrics and gynecology residency in 1992 and serving as administrative chief resident in her final year. In 2002, she continued her medical training at Montefiore Einstein in medical genetics, completing the program in 2004.</p><p>Dr. Klugman&rsquo;s research focuses on novel methods for prenatal screening, testing and diagnosis as well as the assessment of new modalities for the diagnosis and treatment of hereditary cancer syndromes. Her work has been published in peer-reviewed journals, book chapters and other print publications. She was the Reproductive Genetics Editor for <em>Genetics in Medicine</em> and has been a reviewer for journals such as the <em>American Journal of Medical Genetics, Obstetrics and Gynecology and Prenatal Diagnosis</em>. Dr. Klugman has spoken extensively at regional and national medical conferences, including more than 70 international and national invited presentations.</p><p>Dr. Klugman has served on the board of the American College of Medical Genetics since 2015 and will be President from 2023 to 2025. She has completed six-year terms on both the Committee on Genetics of the American Board of Obstetrics and Gynecology and the Residency Review Committee for Medical Genetics for the Accreditation Council of Graduate Medical Education. She is board certified in both obstetrics and gynecology and medical genetics and is listed in several medical directories including <em>Who&rsquo;s Who in Medical Sciences Education</em>, <em>Who&rsquo;s Who in Academic Medicine</em>, <em>New York Magazine</em> Best Doctors list, and Castle Connelly <em>How to Find the Best Metro Area Doctors</em>.</p>

Is Open Scheduling

Off

Julie R. Kaplan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/00af0c80-50ec-11ee-9401-27bda0baf9a7.jpg

First Name

Julie

Last Name

Kaplan

NPI

1225389877

Faculty ID

15443

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Kaplan has a special interest in prenatal care, contraception and colposcopy.</span>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Kaplan's research interests include simulation model research and researching the long-term outcome of estrogenized endometrium in postmenopausal women.</span>

Elsevier Profile

EMR ID

54522

Biography

<p>Julie Kaplan, MD is an attending physician, Assistant Professor of Obstetrics &amp; Gynecology and Women's Health and Medical Student OBGYN Associate Clerkship Director at Montefiore Einstein. She has a special interest in prenatal care, contraception and colposcopy.</p><p>After obtaining her Bachelor of Science in 2008 from Cornell University, Dr. Kaplan earned her Doctor of Medicine in 2012 at SUNY Downstate College of Medicine. She then came to Montefiore Einstein to complete an internship and residency in Obstetrics and Gynecology in 2016.</p><p>Her research interests include simulation model research and researching the long-term outcome of estrogenized endometrium in postmenopausal women. Her work has been published in the American Journal of Obstetrics and Gynecology.</p><p>Dr. Kaplan is board certified in Obstetrics and Gynecology and is a member of the American College of Obstetricians and Gynecologists.</p>

Is Open Scheduling

On

Sara S. Isani

https://assets.montefioreeinstein.org/profiles/images/Isani_Sara_MD_2x.jpg

First Name

Sara

Last Name

Isani

NPI

1992973275

Faculty ID

12996

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Gynecological Oncology</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical focus is on pre-cancers and cancers of the reproductive tract. She performs specialized cancer surgery as well as chemotherapy management of these conditions, and also cares for women with hereditary syndromes that increase risk of gynecologic malignancy.

Research Focus

Dr. Isani&rsquo;s clinical research includes trials to improve cancer survival and quality of life for cancer patients, as well as issues related to access of care.

Elsevier Profile

EMR ID

45793

Biography

<p>Sara Isani, MD, is Attending Physician at Montefiore and Associate Professor of Obstetrics and Gynecology &amp; Women&rsquo;s Health at our Albert Einstein College of Medicine. Her clinical focus is on pre-cancers and cancers of the reproductive tract. She performs specialized cancer surgery as well as chemotherapy management of these conditions, and also cares for women with hereditary syndromes that increase risk of gynecologic malignancy.</p><p>In 2001, Dr. Isani received her Bachelor of Arts in Ecology and Evolutionary Biology from Princeton University. In 2002, she attended New York University School of Medicine, earning her Doctor of Medicine degree in 2006. She started her postgraduate training with an internship and residency in Obstetrics and Gynecology at Yale New Haven Hospital from 2006 to 2010. She then pursued a Gynecologic Oncology fellowship at Albert Einstein College of Medicine, completing the two-year fellowship in 2013.</p><p>Dr. Isani&rsquo;s clinical research includes trials to improve cancer survival and quality of life for cancer patients, as well as issues related to access of care. Her work has been published in peer-reviewed journals, book chapters and abstracts.</p><p>Dr. Isani is board certified in obstetrics and gynecology and gynecologic oncology. She is a member of the Society of Gynecologic Oncology and the American Congress of Obstetrics and Gynecology.</p>

Is Open Scheduling

Off

Laura J. Hodges

https://assets.montefioreeinstein.org/profiles/images/physphoto/Hodges_Laura_MD_420x504.jpg

First Name

Laura

Last Name

Hodges

NPI

1831147438

Faculty ID

16292

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Women&rsquo;s interventional procedures, specifically uterine artery embolization for fibroid disease.

Research Focus

Women&rsquo;s interventional procedures, specifically uterine artery embolization for fibroid disease.

Elsevier Profile

EMR ID

11807

Biography

<p>Laura J. Hodges, MD, is Attending Physician at Montefiore and Assistant Professor of Radiology at our Albert Einstein College of Medicine. Her practice specialty is breast imaging and interventional radiology, with a clinical focus on women&rsquo;s interventional procedures, specifically uterine artery embolization for fibroid disease.</p><p>After receiving her Bachelor of Arts from University of Connecticut in 1985 and her Bachelor of Science from George Washington University in 1987, Dr. Hodges earned her Doctor of Medicine at Albert Einstein College of Medicine in 1994. Upon graduation, she then pursued postdoctoral training at Yale New Haven Hospital, completing a Radiology residency in 1999. She then attended Cornell Medical Center/Sloan Kettering Memorial Cancer Center where she completed a fellowship in Interventional Radiology in 2000.</p><p>Dr. Hodges&rsquo;s research interests build on her clinical focus. She has published a case study on preoperative transcatheter embolization of abdominal pregnancy, as well as a number of abstracts on women&rsquo;s interventional procedures.</p><p>Dr. Hodges is board certified and is a member of several professional societies, including the Society of Interventional Radiology, the American College of Radiology and the American Roentgen Ray Society.</p>

Is Open Scheduling

Off

Susan A. Fineberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/2851b8d0-d526-11eb-af57-a79c115e5bbd.jpg

First Name

Susan

Last Name

Fineberg

NPI

1942380449

Faculty ID

5173

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr Fineberg's clinical focus is on the study of breast disease both neoplastic and benign.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Fineberg's research focus is on the development of new predictive and prognostic biomarkers to be used in breast cancer patients to optimize clinical outcomes, investigation of the role of immunotherapy and standardization of pathologic practices amongst breast pathologists.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p>Lanjewar S, Patil P, <strong>Fineberg S. </strong>Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy- A survey of pathologists in academic institutions across the United States. Modern Pathol. 2019 .(33), 91-98. <a title="Read article" href="https://doi.org/10.1038/s41379-019-0326-5&quot; target="_blank">https://doi.org/10.1038/s41379-019-0326-5</a></p&gt;
<p>Kimberly J. Van Zee, MS, MD, Emily C. Zabor, MS, Rosemarie Di Donato, MD3, Bryan Harmon, MD, Jana Fox, MD, Monica Morrow, MD, Hiram S. Cody III, MD, <strong>Susan A. Fineberg, MD. </strong>A Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Vs Refined Oncotype DX Breast DCIS Score. Annals of Sugical Oncology . 2019 (26), 212-213. <a title="Read article" href="https://doi.org/10.1245/s10434-019-07537-4&quot; target="_blank">https://doi.org/10.1245/s10434-019-07537-4</a></p&gt;
<p>Didonato R, Shapiro N, Koenigsberg, D&acirc;&euro;&trade;Alfonso, T, Jaffer S, <strong>Fineberg S</strong>. Invasive Mucinous Carcinoma of the breast and Response Patterns After Neodjuvant Chemotherapy. Histopathology 2018 May; 72(6):965-973</p>
<p>Hazan, R, Suyamaa, K, Yao J, Liang H, Bernard , Loudig O Amgalm D, Mckimplson W, Phillops G, Segall J, Wang Y, <strong>Fineberg S,</strong> Norton L, Kitsis R. A paradoxical role for an Akt3 splice variant lacking serine 472 phosphorylation site in promoting apoptosis leading to suppression of mammary tumorigenesis. Cancer Research. 2018:78(1).103-114</p>
<p>Pearlman A, Upadhyay K, Cole K, Loke J, Suan K, <strong>Fineberg S,</strong> Freedland S, Shao Y, Ostrer H. Robust genomic copy number predictor of pan cancer metastasis. Genes and Cancer. 2018 <a title="Read article" href="https://doi.org/10.18632/genesandcancer.165&quot; target="_blank">https://doi.org/10.18632/genesandcancer.165</a></p&gt;
<p>Guo Tianhua, Shapiro Nella, Wang Yihong, <strong>Fineberg Susan</strong>. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: Clinicopathologic features and correlation with subsequent excision.Clinical Breast Cancer 2018 (4) e449-454 DOI: /10.1016/j.clbc.2017.10.004</p>
<p>Mclemore L Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, <strong>Fineberg S.</strong> An immunoscore using PD-L1, CD68 and tumor infiltrating lymphocytes (TILs) to predict response to neoadjuvant chemotherapy in invasive breast cancer. Appl Immunohistochem Mol Morphol.2018;26(9), 611-619. doi: 10.1097/PAI.0000000000000485</p>
<p>Maria-Vittoria Dieci, Nina Radosevic-Robin, <strong>Susan Fineberg</strong> et. al., on behalf of the International Immuno-Oncology Bio-marker Working Group* Update on Tumor Infiltrating Lymphocytes (TILs) in Breast Cancer, including recommendations to assess TILs in Residual Disease and DCIS: a report of the International Immuno-Oncology Biomarker Working group on Breast Cancer*. Seminars in Cancer Biology 2107:52.16-25. <a title="Persistent link using digital object identifier" href="https://doi.org/10.1016/j.semcancer.2017.10.003&quot; target="_blank">https://doi.org/10.1016/j.semcancer.2017.10.003</a></p&gt;
<p>Mantilla JG, Koenigsberg T, Reig B, Shapiro N, Villaneuva-Siles E, <strong>Fineberg S.</strong> Core biopsy of vascular neoplasms of the breast; Pathologic features , imaging and clinical findings. Amer J of Surg Pathol .2016; 40:1424-1434</p>
<p>Polley M, Leung S, Gao D, Mastropasqua M, Zabaglo L, Bartlett J, McShane L, Enos R, Badve S, Bane A, Borgquist S, <strong>Fineberg S</strong>, Lin M, Grabau A, Gutierrez C, Hugh J, Moriya T, Ohi Y, Osborne K, Penault-Llorca F, Piper T, Porter P, Sakatani T, Salgado R, Starczynski J, L&Atilde;&brvbar;nkholm A, Viale G, Dowsett M, Hayes D, Nielsen T, on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG). An international study to increase concordance in Ki67 scoring. Modern Pathology .2015; 28 (6) :778. PubMed [citation] PMID 25698062</p>
<p>Diaz J, Stead L, Shapiro N, Newell R, Loudig O, Lo Y, Sparano J, <strong>Fineberg S</strong>. Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. Breast Cancer Research and Treatment. 2013; 138 :91-97. PubMed [citation] PMID 23417359</p>
<p>Giricz, O, Reynolds P, Rammuauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro, N <strong>, Fineberg S,</strong> Kenny P, Loudig O. Has-miR375 is differentially expressed during lobular neoplasia and promotes loss of mammary acinar polarity. Journal of Pathology. 2012; 226 (1): 108-119 .PubMed [citation] PMID 21953071</p>
<p>Auerbach J, Kim M, <strong>Fineberg S</strong>. Can results of routine pathologic evaluation of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX Assay Recurrence Score result? Archives of Pathology and Laboratory Medicine. 2010; 134, (11): 1697-1701. PubMed [citation] PMID 21043825</p>
<p>Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, deng HF, Ament PS, <strong>Fineberg S,</strong> Pestell RG, Carasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nature Medicine .2000; 6 (8): 871-878. PubMed [citation] PMID: 10932223</p>
<p>Casey M, Zimmerman J, Rosenblatt R, <strong>Fineberg S.</strong> Mastectomy without malignancy following carcinoma diagnosed by large core stereotactic breast biopsy. Modern Pathology.1997; 10 (12): 1209-1213. PubMed [citation] PMID: 9436965</p>
<p><strong>Fineberg S</strong>, Rosen P. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 1994; 102 (6): 757-762. PubMed [citation] PMID: 7801888</p>

EMR ID

3791

Biography

<p>Susan Fineberg, MD, is an Attending Pathologist, Section Head Breast Pathology and Associate Professor, Pathology at Montefiore Einstein. An integral member of the multidisciplinary breast program leadership team, Dr. Fineberg&rsquo;s clinical focus is the study of tissue to diagnose breast disease, both neoplastic and benign.</p><p>After receiving her Bachelor of Arts in chemistry from State University of New York (SUNY) Binghamton in 1983, Dr. Fineberg pursued her medical degree at SUNY Stonybrook School of Medicine, earning her Doctor of Medicine in 1987. She completed her anatomic and clinical pathology residency training at New York University Medical Center in 1992, followed by an oncologic surgical pathology fellowship at Memorial Sloan Kettering Cancer Center in 1993.</p><p>Dr. Fineberg's research focus includes biomarker development in invasive breast cancer, particularly in the neoadjuvant setting, prognostic and predictive markers for ductal carcinoma in situ progression and recurrence, the role of immune response in breast cancer progression, and standardization of practice among breast pathologists. She has over 60 peer-reviewed publications on breast disease, has authored book chapters on the subject and has presented her work at national meetings.</p><p>Dr. Fineberg is board certified and is an active member of many national and international pathology organizations including the United States and Canadian Academy of Pathology, the International Society of Breast Disease and the International TILs Immuno-Oncology Biomarker Working Group for Breast Cancer.</p>

Is Open Scheduling

Off